Strongbridge Biopharma plc was a big mover last session, as the company saw its shares rise over 10% on the day. The move came after the company met its enrollment target of 90 patients in the Phase 3 SONICS study. The study evaluated the safety and efficacy of RECORLEV (levoketoconazole), a next-generation cortisol synthesis inhibitor, for the treatment of endogenous Cushing’s syndrome. This led to far far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 39% in the past one-month time frame.

 

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

 

Strongbridge Biopharma currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

 

 

A better-ranked stock from the Medical - Biomedical and Genetics space is Regeneron Pharmaceuticals, Inc. (REGN Quick QuoteREGN - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

 

Is SBBP going up? Or down? Predict to see what others think: Up or Down

 

Today's Stocks from Zacks' Hottest Strategies                                 

 

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.     

 

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>